Bioasis Technologies Inc. and Aposense Enter into a Research Collaboration
March 31, 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 31, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSXV:BTI; OTCQB:BIOAF), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Publication of CNS Delivery of siRNA via xB³ ™ Platform Technology
March 29, 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing
March 24, 2021 17:15 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 24, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;), (“Bioasis” or the “Company”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Technologies Inc. Announces Warrant Extension and Repricing
March 22, 2021 18:30 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”) a pre-clinical, research-stage biopharmaceutical company...
Bioasis to Attend and Present at Upcoming Investor and Industry Conferences
March 08, 2021 16:05 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., March 08, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Shares for Debt Transaction
February 10, 2021 19:02 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™...
Bioasis Announces $200,000 Non-Brokered Private Placement
January 29, 2021 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™...
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020
January 27, 2021 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Stock Option Grant
January 22, 2021 09:19 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™...
Bioasis to Present at Upcoming Industry Conferences
January 04, 2021 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...